Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMC 3437608)

Published in Chemother Res Pract on September 02, 2012

Authors

Masooma Sultani1, Andrea M Stringer, Joanne M Bowen, Rachel J Gibson

Author Affiliations

1: School of Medical Sciences, University of Adelaide, North Terrace, Adelaide, SA 5005, Australia.

Articles citing this

Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells (2014) 1.14

Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med (2015) 0.97

TLR1, 2, 4, 6 and 9 Variants Associated with Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.93

Portrait of inflammatory response to ionizing radiation treatment. J Inflamm (Lond) (2015) 0.89

Cytokine levels (IL-4, IL-6, IL-8 and TGFβ) as potential biomarkers of systemic inflammatory response in trauma patients. Int Orthop (2014) 0.87

IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol (2014) 0.87

Critical role for IL-1β in DNA damage-induced mucositis. Proc Natl Acad Sci U S A (2014) 0.81

Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget (2016) 0.80

Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy. Cancers (Basel) (2014) 0.79

Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. Onco Targets Ther (2016) 0.78

Regulatory T Cells Contribute to the Inhibition of Radiation-Induced Acute Lung Inflammation via Bee Venom Phospholipase A₂ in Mice. Toxins (Basel) (2016) 0.77

Effect of malaria components on blood mononuclear cells involved in immune response. Asian Pac J Trop Biomed (2013) 0.77

Identification of TLR2/TLR6 signalling lactic acid bacteria for supporting immune regulation. Sci Rep (2016) 0.76

Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Support Care Cancer (2014) 0.75

Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling. Oncotarget (2017) 0.75

Palifermin and Chlorhexidine Mouthwashes in Prevention of Chemotherapy-Induced Mucositis in Children with Acute Lymphocytic Leukemia: a Randomized Controlled Trial. J Dent (Shiraz) (2016) 0.75

The Effect of Quercetin on Pro- and Anti-Inflammatory Cytokines in a Prenatally Stressed Rat Model of Febrile Seizures. J Exp Neurosci (2017) 0.75

Articles cited by this

(truncated to the top 100)

Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63

Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81

IL-10 inhibits cytokine production by activated macrophages. J Immunol (1991) 13.13

Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 9.82

NF-kappaB: a key role in inflammatory diseases. J Clin Invest (2001) 9.66

Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42

Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 6.61

The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol (1999) 6.19

Proinflammatory cytokines. Chest (2000) 5.89

The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol (1993) 5.88

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30

Anti-inflammatory cytokines. Chest (2000) 4.74

The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol (2009) 4.53

Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med (1993) 4.30

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 3.83

Interleukin-10 therapy--review of a new approach. Pharmacol Rev (2003) 3.51

Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol (2000) 3.34

Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis (2000) 3.03

Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer (2007) 2.95

Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature (1987) 2.94

Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med (2000) 2.93

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest (1990) 2.83

Cytokines in acute and chronic inflammation. Front Biosci (1997) 2.67

Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol (2007) 2.60

Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology (1995) 2.38

Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24

Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21

Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A (1996) 2.18

Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene (2001) 2.17

Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest (1991) 2.08

IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol (2007) 1.96

Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol (2007) 1.92

Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J (1994) 1.70

Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol (1998) 1.70

Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol (1996) 1.60

Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut (2000) 1.55

Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene (2003) 1.52

Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A (1992) 1.48

The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47

The systemic pro-inflammatory response in sepsis. J Innate Immun (2010) 1.43

Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med (1997) 1.41

Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol (2007) 1.37

The biological properties of interleukin-1. Eur Cytokine Netw (1995) 1.36

Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35

IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur J Immunol (1998) 1.33

Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis (2000) 1.30

A biological approach to mucositis. J Support Oncol (2004) 1.29

Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother (2007) 1.29

IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol (2004) 1.28

Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res (2007) 1.22

Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut (1997) 1.21

Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia (1999) 1.16

The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med (2002) 1.15

Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) (1997) 1.14

IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (1994) 1.14

The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol (2004) 1.13

IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol (1997) 1.12

Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12

Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10

IL-1 expression in human monocytes is transcriptionally and posttranscriptionally regulated by IL-4. J Immunol (1991) 1.09

Structure and mechanism in NF-kappa B/I kappa B signaling. Cold Spring Harb Symp Quant Biol (1999) 1.09

Diagnosis and management of oral mucositis. J Support Oncol (2007) 1.08

A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood (1994) 1.07

Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07

Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05

Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck (2003) 1.05

Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05

Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med (2009) 1.03

Pathobiology of mucositis. Semin Oncol Nurs (2004) 1.03

Induction of nuclear factor kappa B after low-dose ionizing radiation involves a reactive oxygen intermediate signaling pathway. Radiat Res (1994) 1.02

Multiple treg suppressive modules and their adaptability. Front Immunol (2012) 1.01

Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00

Gastrointestinal mucositis. Semin Oncol Nurs (2004) 1.00

Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci (2002) 0.99

Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice. Cancer Chemother Pharmacol (2010) 0.98

Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest (1998) 0.98

Staphylococcus aureus-induced septic arthritis and septic death is decreased in IL-4-deficient mice: role of IL-4 as promoter for bacterial growth. J Immunol (1998) 0.98

Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells. J Interferon Cytokine Res (2001) 0.97

Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol (2007) 0.94

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93

The interleukin-4 site-2 epitope determining binding of the common receptor gamma chain. Eur J Biochem (1998) 0.93

A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kappaB. Oncogene (1998) 0.92

Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92

Murine interleukin-11 (IL-11) is expressed at high levels in the hippocampus and expression is developmentally regulated in the testis. J Cell Physiol (1996) 0.92

Gastrointestinal mucositis: a new biological model. Support Care Cancer (2003) 0.92

Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am J Physiol (1997) 0.91

Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion (2001) 0.91

Bacterial components induce cytokine and intercellular adhesion molecules-1 and activate transcription factors in dermal fibroblasts. Res Microbiol (2003) 0.90

The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Ann Med (1997) 0.88

Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy (2007) 0.85

Expression of murine interleukin 11 and its receptor alpha-chain in adult and embryonic tissues. Stem Cells (1997) 0.83

The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol (1995) 0.83

Radiation therapy-induced mucositis: relationships between fractionated radiation, NF-kappaB, COX-1, and COX-2. Cancer Treat Rev (2006) 0.82

Interleukin-11. BioDrugs (1997) 0.81

IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica (1998) 0.81

Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-Fluorouracil in a mouse mucositis model. Biomed Pharmacother (2011) 0.81

Articles by these authors

Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24

Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13

The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47

Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35

Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27

Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12

Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12

Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10

Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07

Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07

Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06

Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05

Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05

Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05

Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01

Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00

Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology (2005) 1.00

Gastrointestinal mucositis. Semin Oncol Nurs (2004) 1.00

Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99

Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97

A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther (2007) 0.96

Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93

Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs (2008) 0.93

Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93

VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther (2007) 0.93

Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care (2009) 0.93

Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92

Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol (2012) 0.91

Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91

Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) (2007) 0.89

Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88

Biomarkers of regimen-related mucosal injury. Cancer Treat Rev (2011) 0.87

Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) (2010) 0.85

Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy (2007) 0.85

Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol (2009) 0.85

Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer (2007) 0.85

Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors. Exp Biol Med (Maywood) (2013) 0.84

Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care (2013) 0.84

Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma. J Gastrointest Surg (2015) 0.84

The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem! Cancer Biol Ther (2006) 0.80

Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol (2006) 0.80

Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther (2007) 0.80

Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs (2008) 0.80

Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs (2007) 0.80

Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Support Care Cancer (2014) 0.79

The urgent need for an effective biomarker for cytotoxic therapy-induced adverse effects. Curr Opin Support Palliat Care (2013) 0.79

Severe mucositis: how can nutrition help? Curr Opin Clin Nutr Metab Care (2007) 0.79

Technological advances in mucositis research: new insights and new issues. Cancer Treat Rev (2008) 0.78

New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opin Biol Ther (2014) 0.77

Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther (2012) 0.77

Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy (2011) 0.77

Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. J Support Oncol (2013) 0.76

Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Support Palliat Care (2016) 0.76

Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Int J Exp Pathol (2011) 0.76

Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemother Pharmacol (2014) 0.76

TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity? Int J Cancer (2014) 0.76